natgillin/translations-raw huggingface dataset:
The use of a combination of any one of claims 1-7 for the manufacture of a medicament for the treatment or prevention of conditions which can be ameliorated by the inhibition of poly(ADP-ribose) polymerase (PARP). 
Primjena spoja prema bilo kojem od zahtjeva 1 do 9, ili njegove farmaceutski prihvatljive soli, stereoizomera ili tautomera, naznačena time što služi za proizvodnju lijeka za liječenje ili prevenciju stanja koja se mogu poboljšati inhibicijom poli(ADP-riboza) polimeraze (PARP).
The method of claim 6, wherein the solvent comprises a carboxylic acid and water; optionally wherein the volume ratio of the carboxylic acid versus water is ranging from about 0.1 to about 10, or from about 1 to about 5, or is about 1. 
Postupak u skladu s patentnim zahtjevom 6, naznačen time što otapalo sadrži karboksilnu kiselinu i vodu; gdje se volumni omjer između karboksilna kiselina 1 vode može kretati u rasponu od otprilike 0,1 do otprilike 10, ili od otprilike 1 do otprilike 5, ili je otprilike 1.
in the form of tetra-n-butyl ammonium fluoride (TBAF) under conditions closely related to those reported by Arnould et al. 
u obliku tetra-1-butil amonijevog fluorida (TBAF) u uvjetima vrlo sličnima onima opisanima u Arnould i sur.
The method of claim 1, wherein the endogenous mouse Vλ gene segments of the second endogenous Vλ-Jλ-Cλ gene cluster have been replaced with a contiguous sequence of the human immunoglobulin λ light chain locus that spans from a human Vλ3-27 gene segment to a human Vλ3-1 gene segment and a contiguous sequence of the human immunoglobulin λ light chain locus that spans from a human Vλ5-52 gene segment to a human Vλ1-40 gene segment. The method of claim 1, wherein the human Vλ and Jλ gene segments comprise at least 12 human Vλ gene segments. 
Genetski modificirani miš prema zahtjevu 1, naznačen time, što miš u svom genomu dodatno sadrži endogeni lokus imunoglobulina lakog lanca K koji se sastoji od zamjene endogenih VK 1 JK genskih segmenta neraspoređenim humanim VA i JA genskim segmentima, te naznačen time, što su humani VA 1 JA genski segmenti operativno povezani s endogenim mišjim CK genom tako da miš izražava imunoglobulinski laki lanac koji sadrži humanu varijabilnu regiju A spojenu s mišjom konstantnom regijom K.
The formulation of claim 3 wherein bG-CSF- T133pAF-20K PEG is present in an amount of between 0.5 and 12 grams/liter, the buffer is citrate and said citrate buffer has a molarity of about 30 mM, arginine has a molarity of about 250 mM, and wherein the formulation has a pH value of about 6.0. 
Formulacija u skladu s patentnim zahtjevom 3, naznačena time što je bG-CSF-T133pAF-20K PEG prisutan u količini između 0,5 i 12 g/l, pufer je citratni, a navedeni citratni pufer ima molarnost od otprilike 30 mM, arginin ima molarnost od otprilike 250 mM, te što formulacija ima pH vrijednost od otprilike 6,0.
The method of claim 44, wherein the pain is chronic pain. 
Tvar ili farmaceutski sastav za uporabu definiranu u patentnom zahtjevu 27, pri čemu je bol kronična bol.
10–12 shows cross-sectional views of the packaging, and 
prikazuje stanje tehnike pakiranja, i
A compound B: and salts and solvates thereof. 
Spoj, naznačen time, da je A: i njegove soli i njegovi solvati.
is hydrogen, C1 to C12 alkyl, phenyl unsubstituted or substituted by C1 to C12 alkyl or COR6 acyl group; R6 being hydrogen, C1 to C12 straight chain or branched alkyl, phenyl or benzoyl, respectively unsubstituted or substituted by C1 to C12 alkyl, or any group leading to hydroxyl upon biological metabolization or chemical deprotection, particularly an ester, ether, acetale, carbonate, carbamate, phosphate, phosphonate, ketal, sulfate, or sulfonate; and salts thereof, for use in a medical treatment as angiogenesis inhibitor, wherein said compound is 4-hydroxytestosterone or its salts or esters. 
je vodik, C1 do C12 alkil, fenil koji nije supstituiran ili je supstituiran s C1 do C12 alkilnom ili COR6 acilnom skupinom; R6 je vodik, C1 do C12 nerazgranati ili razgranati alkil, fenil ili benzoil, koji odgovarajuće nije supstituiran ili je supstituiran s C1 do C12 alkilnom, ili bilo kojom skupinom koja se pretvara u hidroksilnu biološkim metaboliziranjem ili kemijskim uklanjanjem zaštite, osobito estera, etera, acetala, karbonata, karbamata, fosfata, fosfonata, ketala, sulfata ili sulfonata; i njihovih soli, naznačen time što je namijenjen upotrebi u medicinskom liječenju kao inhibitor angiogeneze, gdje je navedeni spoj 4-hidroksitestosteron, ili njegove soli ili esteri.
The dosing device comprised a rotation pump by which the velocity of the addition of the modifying agent was adjusted. 
HR P20080463 T3 Uređaj za doziranje se sastoji od rotacijske crpke kojom se prilagodi brzina dodavanja modificirajućeg agensa.
The panel according to any claims 1 to 8 characterized in that the attaching of attachable elements (13) is executed by means of cold fusion of two material without their destruction. 
Panel prema bilo kojem od zahtjeva 1 do 8, naznačen time što se pričvršćivanje pričvrsnih elemenata (13) izvodi postupkom spajanja na hladno dva materijala, bez njihovog oštećivanja.
a nucleotide sequence encoding at least one glycosyltransferase from a first prokaryotic organism, optionally a Gram-positive bacterium; 
nukleotidni slijed koji kodira najmanje jednu glikozil-transferazu iz Gram-pozitivne bakterije, gdje je navedena Gram-pozitivna bakterija Staphylococcus aureus;
The temperature of the fluidization air was set at 25 °C in the first part of the pelletization and to 40°C for the drying procedure. 
Temperatura zraka za fluidiziranje održavana je na 25?C tijekom prvog dijela granuliranja i na 40*C tijekom postupka sušenja.
a T cell receptor a-chain comprising at least one, preferably two, more preferably all three of the CDR sequences of a T cell receptor a-chain selected from the group consisting of SEQ ID NOs: 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26 and 28 or a variant thereof and 
(ii) B-lanac T staničnog receptora koji sadrži sve tri CDR sekvence B-lanca T staničnog receptora od SEK IDBR:x +1; naznačen time, da je x odabran iz skupine sastavljene od 6, 8, 10, 12, 14, 16, 18, 20, 22,24, 26128 i
Nebuliser delivery of the lead dAbs: 
Datum objave europske prijave patenta:
A compound having the structure: or a pharmaceutically acceptable salt thereof, for use in a method of reducing antipsychotic induced weight gain. 
Spoj slijedeće strukture: r ili njegova farmaceutski prihvatljiva sol, za uporabu u postupku smanjenja antipsihotički induciranog dobivanja na težini.
A compound according to any of claims 1 to 7, wherein R2 and R'2, which may be the same or different, each represents a methyl or ethyl group, or, together with the nitrogen atom to which they are linked, form a morpholinyl, thiomorpholinyl, piperazinyl, homopiperazinyl, or piperidinyl group, optionally substituted at least one substituent selected from the group consisting of: chlorine atoms, hydroxyl groups, trifluoromethyl groups, alkoxy groups, hydroxyalkyl groups, and alkyl groups. 
Spoj prema bilo kojem od zahtjeva 1 do 7, naznačen time da R2 i R'2, koji mogu biti isti ili različiti, svaki predstavlja metil ili etilnu skupinu, ili, zajedno sa atomom dušika na koji su spojeni, formiraju morfolinil, tiomorfolinil, piperazinil, homopiperazinil, ili piperidinil skupinu, proizvoljno supstituiranu sa barem jednim supstituentom odabranim iz skupine koja sadrži: atome klora, hidroksilne skupine, trifluorometilne skupine, alkoksi skupine, hidroksialkilne skupine, te alkilne skupine.
Magnesium stearate was screened into the blender and the mixing process continued for a further 2 minutes at 17 rpm. 
Magnezij stearat se prosije u miješalicu i postupak miješanja nastavi daljnje 2 minute pri 17 okr/min.
Typically said respiratory disease is asthma, acute or chronic bronchitis, emphysema, chronic obstructive pulmonary disease (COPD), bronchial hyperreactivity or rhinitis, in particular asthma or chronic obstructive pulmonary disease (COPD). 
Uporaba u skladu s patentnim zahtjevom 10, naznačena time, da je bolest dišnih putova astma ili kronična opstruktivna bolest pluća (COPD). .
number of cells per well (thousands) 
(21) Broj predmeta:
The method of item 64 or the compound, the polymorphic form, or the pharmaceutical composition for use according to item 64, or the use of item 64, wherein the liver disease is fatty liver disease or hepatitis. 
Spoj, polimorfni oblik ili farmaceutski pripravak za upotrebu prema zahtjevu 11, naznačen time da stanje je bolest jetre odabrana od bolesti masne jetre i hepatitisa.
In a further on preferred embodiment of the invention, the neurological disorder to be treated or diagnosed with the VLP of the invention is multiple sclerosis. 
Virusu slična čestica (VLP) za uporabu sukladno barem jednom od gore navedenih patentnih zahtjeva, gdje je neurološki poremećaj multipla skleroza.
The method of anyone of the preceding claims, wherein the effluent stream is cooled at the same time that the sorbent particles are introduced into the effluent stream. 
Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što se izlazna struja ohladi istodobno s unošenjem čestica sorbensa u izlaznu struju.
The monoclonal antibody or antigen binding fragment thereof of claim 1, which binds to CCL3/MIP-1a, CCL4/MIP-1B, and CCL5/RANTES and which does not bind to CCL2/MCP-1, comprising a heavy and light chain CDR sequence combination (HCDR1/HCDR2/HCDR3/LCDR1/LCDR2/LCDR3) selected from the group consisting of SEQ ID NOS: 33/34/35/38/39/40 and 63/64/65/68/69/70, or which competes for binding to CCL3/MIP-1a, CCL4/MIP-1B, and CCL5/RANTES, with an antibody or antigen binding fragment comprising a heavy and light chain CDR sequence combination selected from the group consisting of SEQ ID NOS: 33/34/35/38/39/40 and 63/64/65/68/69/70. 
Monoklonsko protutijelo, ili njegov fragment koji veže antigen, u skladu s patentnim zahtjevom 1, naznačeno time, da se veže na CCL3/MIP-1a, CCL4/MIP-1(, i CCLS/RANTES i koji se ne veže na CCL2/MCP-1, koji obuhvaća kombinacije CDR nizova teških 1 lakih lanaca (HCDR1I/HCDR2/HCDR3/LCDR 1/LCDR2/LCDR3) odabranih iz skupine koja se sastoji od SEQ ID NOS: 33/34/35/38/39/40 i 63/64/65/68/69/70, ili koji se natječe za vezanje na CCL3/MIP-10, CCL4/MIP-1f, i CCLS/RANTES, s antitijelom ili fragmentom koji veže antigen i sadrži kombinacije CDR nizova teških 1 lakih lanaca odabrane 1z skupine koju čine CEQ ID NO: 33/34/35/38/39/40 i 63/64/65/68/69/70.
The polyvinylpyrrolidone and polaxomer 188 solution was added over a period of fifteen minutes to the mixture containing clarithromycin and mixed in the granulator at 62 mL/min at the above settings. 
Otopina polivinilpirolidona i Polaksomera 188 se doda tijekom razdoblja od petnaest minuta u smjesu koja sadrži klaritromicin i miješa se u granulatoru na 62 ml/min uz gore navedene uvjete.
The peptide, the nucleic acid or an expression vector, the cell, or the activated cytotoxic T lymphocyte for use according to claim 13, wherein said medicament is a vaccine. 
Peptid, nukleinska kiselina ili ekspresijski vektor, stanica, aktivirani citotoksični T-limfocit za upotrebu u skladu s patentnim zahtjevom 13, pri čemu se navedeni peptidi koriste kao cjepivo.
is selected from the group consisting of hydrogen, methyl, and nitrogen-protecting group; 
je odabran iz skupine koju sačinjavaju vodik i halo;
releasing, after a successful pressure test, the pressure from the first volume; and 
nakon uspješnog tlačnog ispitivanja otpušta se tlak iz prvog volumena (V1), i
The pharmaceutical composition according to claims 8 to 12, wherein the TNFa inhibitor is an anti-TNFa antibody. 
Farmaceutski pripravak u skladu s patentnim zahtjevima 8 do 12, naznačen time, da TNFa inhibitor je protu-TNFa protutijelo.
3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione and the second active agent for use according to claim 13, wherein the second active agent is rituximab. 
-(4-Amino-1-okso-1,3-dihidroizoindol-2-il)piperidin-2,6-dion i drugo aktivno sredstvo, namijeni upotrebi u skladu s patentnim zahtjevom 13, naznačeni time što drugo aktivno sredstvo je rituksimab.
The compositions for use in accordance with embodiments of the present invention may also comprise at least one coemulsifying compound, such as oxyethylenated sorbitan monostearate, fatty alcohols such as stearyl alcohol or cetyl alcohol, or esters of fatty acids and polyols, such as glyceryl stearate, but not limited thereto. 
Sredstvo sukladno patentnom zahtjevu i, naznačeno time, da farmaceutski prihvatljivi ekscipijenti 1 / ili nosači dodatno biraju iz barem jednog koemulzijskog sredstva koje uključuju oksietilenirani sorbitan monostearat, masne alkobole kao stearilni alkohol ili cetilni alkohol, ili estere masnih kiselina i poliole kao što je gliceril stearat.
A peptide as claimed in claims 1 or 2, formulated for enteral administration. 
Peptid za koji se traži zaštita u patentnim zahtjevima 1 ili 2, formuliran za enteralnu primjenu.
In another aspect, provided herein are host cells comprising the isolated nucleic acids encoding the above IL-2 muteins or IL-2 mutein Fc-fusion proteins. The host cell may be a prokaryotic cell, such as E. coli, or may be a eukaryotic cell, such as a mammalian cell. 
Stanica domaćin koja sadrži izoliranu nukleinsku kiselinu prema patentnom zahtjevu 7 ili patentnom zahtjevu 8 naznačena time što je navedena stanica domaćin prokariotska stanica kao što je E. coli ili eukariotska stanica kao što je stanica sisavca uključujući, ali bez ograničenja na staničnu liniju jajnika kineskog hrčka (CHO).
In a further preferred embodiment, said mutated lower hinge and/or CH2 domains comprise at least one substitution at amino acids positions 235 and/or 236 (numbering according to Kabat). 
Bispecifično IgG protutijelo sukladno patentnom zahtjevu 6, naznačeno time što navedeni mutirani CH2 i/ili niže zglobne domene sadrže najmanje jednu supstituciju na aminokiselinskom položaju 235 i/ii 236 (numercija sukladno Kabat-u).
The compound or composition for use of claim 13, wherein the neurological disease is selected from relapsing-remitting multiple sclerosis, secondary progressive multiple sclerosis, primary progressive multiple sclerosis, or progressive relapsing multiple sclerosis. 
Spoj ili pripravak namijenjeni upotrebi u skladu s patentnim zahtjevom 13, naznačeni time što se neurološku bolest bira između recidivirajuće-remitirajuće multiple skleroze, sekundarne progresivne multiple skleroze, primarne progresivne multiple skleroze ili progresivne recidivirajuće multiple skleroze.
The method of claim 1 wherein said calculating a differential comprises obtaining a sequence density of an abnormally distributed chromosome and comparing it to a sequence density of a disomic chromosome. 
navedeno određivanje razlike obuhvaća dobivanje gustoće obilježavajućih sekvenci abnormalno raspoređenih kromosoma i njezino uspoređivanje s vrijednošću disomnog kromosoma;
System according to claim 12, wherein the transport means (25) comprises a conveying belt (27) driven by a motor (26). 
Sustav u skladu s patentnim zahtjevom 13, naznačen time što transporter (25) ima transportnu vrpcu (27), pogonjenu motorom (26).
A compound of general formula (I), or a stereoisomer, pharmaceutically acceptable salt or hydrate thereof, wherein, 
3 a au? Na Å oče M E oo ili stereoizomer, farmaceutski prihvatljiva sol ili hidrat istog, pri čemu
A feed containing conventional feed ingredients and conventional additives and other auxiliary agents, characterized in that the feed contains inside and on the surface of feed raw material particles a fatty acid mixture in which the content of saturated fatty acids is more than 90% and the feed comprises an emulsifier, wherein the amount of emulsifier is 0.01-1.0% by weight of the feed. 
Postupak pripreme životinjske hrane, naznačeno time da se među konvencionalne sastojke životinjske hrane i konvencionalne aditive životinjske hrane te pomoćna sredstva dodaje, miješanjem, mješavina masnih kiselina u kojoj je udio zasićenih masnih kiselina veći od 90% i iznos mješavine masnih kiselina u životnjskoj hrani od 1 do 10% težine, te naznačeno time da mješavina masnih kiselina sadrži sljedeće masne kiseline u %:
proteins in an amount of 15-50%, preferably 16-40%, more preferably 17-35% by weight, 
- < bjelančevine u iznosu od 15 do 50%, poželjno od 16 do 40%, poželjnije od 17 do 35% težine,
An anti-EpCAM antibody or a functional derivative thereof wherein the variable region of the antibody heavy chain comprises all three complementarity determining regions (CDRs) having the sequence of SEQ ID No.2; SEQ ID No. 4 and SEQ ID No. 6 and wherein the variable region of the antibody light chain comprises all three complementarity determining regions (CDRs) having the sequence of SEQ ID No.8; SEQ ID No. 10 and SEQ ID No. 12. 
Protutijelo protiv EpCAM, ili njegov funkcionalni derivat, naznačeni time što varijabilno područje teškog lanca protutijela sadrži sva tri područja koja određuju komplementarnost (CDR), čiji su sljedovi SEQ ID No.2; SEQ ID No.4 odnosno SEQ ID No.6, te time što varijabilno područje lakog lanca protutijela sadrži sva tri područja koja određuju komplementarnost (CDR), čiji su sljedovi SEQ ID No.8; SEQ ID No.10 odnosno SEQ ID No.12.
Whole brains from male Wistar rats (125-225 g), excluding cerebellum, are homogenized in 0.32 M sucrose supplemented with 1 mM nialamid with a glass/teflon homogenizer. 
Cijeli mozak Wistar štakora muškog spola (125-225 g) bez cerebelluma, homogeniziran je u 0.32 M sukroze kojoj je dodano 1 mmM nialamida sa staklenim/teflonskim homogenizatorom.
The layer of pure drug comprises about 100% of a pharmaceutical substance, independently selected from, for example, anastrozole, apomorphine, beraprost, buprenorphine, buserelin, dutasteride, finasteride, haloperidol, iloprost, L-thyroxine, L-triiodothryonine, leuprolide, lisuride, nalmefene, nicotine, pramipexole, rasagiline, risperidone, ropinerole, rotigotine, selegiline, sirolimus, tacrolimus, tamsulosin, or testosterone. In one embodiment, the pharmaceutical substance in both the single layer and the layer of pure drug is buprenorphine. 
Uređaj prema patentnom zahtjevu 1, naznačen time, što su farmaceutska tvar prvog sloja i jedna ili više dodatnih farmaceutskih tvari zasebno odabrane iz skupine koja se sastoji od: ropinirola, L-triiodotironina, buprenorfina, anastrozola, apomorfina, beraprosta, buserelina, dutasterida, finasterida, haloperidola, iloprosta, L-tiroksina, leuprolida, lisurida, nalmefena, nikotina, pramipeksola, rasagilina, risperidona, rotigotina, selegilina, sirolimusa, takrolimusa, tamsulosina i testosterona.
specifically binds to toxin B with a KD of less than 20 x 10-6 M. 
specifčno se veže za toksin B sa KD od manje od 20 x 10-6 M.
n+1 first winches which are respectively connected to the n+1 first lines and adapted to wind and unwind independently each of the n+1 first lines; 
n+1 prvih vitla (13) koja su odgovarajuće spojena na n+1 prvih konopaca (14) i prilagođena su za namatanje i odmatanje neovisno svakog od n+1 prvih konopaca;
A "unit dose" is a predetermined quantity of the active compound of the present invention, calculated to produce the desired therapeutic effect, in association with one or more pharmaceutically acceptable excipients. 
Kao primjer, oblik jedinice doziranja može biti kapsula ili tableta, ili nekoliko kapsula ili tableta. "jedinična doza" je prethodno određena količina aktivnog spoja prema ovom izumu, za koju je izračunato da će dovesti do željenog terapijskog učinka, u kombinaciji s jednom ili više farmaceutski prihvatljivih pomoćnih tvari.
The antibody or antigen binding portion thereof according to claim 3, characterized in that said antibody or antigen binding portion thereof has an IC50 less than 1µM, preferably less than 100nM and more preferably less than 20nM as measured in a cell-based Wnt signalling assay in HEK293 cell lines in the presence of sclerostin. 
4. Protutijelo ili njegov dio koji veže antigen prema zahtjevu 3, naznačeno time da navedeno protutijelo ili njegov dio koji veže antigen ima vrijednost IC5, manju od 1 uM, poželjno manju od 100 nM i poželjnije manju od 20 nM kako je mjereno sa staničnim testom Wnt signalizacije kod HEK293 staničnih linija u prisutnosti sklerostina.
Measurements can be performed on specific instrumentation, or can be performed on a fluorimeter with excitation and emission monochrometers set at the same wavelength (e.g. 
Mjerenja se mogu izvoditi na specifičnom instrumentariju, ili se mogu izvoditi na fluorimetru uz ekscitaciju i emisiju kompletom monokrometra na istoj valnoj duljini (na pr.
The composition of claim 9, wherein the second pharmaceutical agent is selected from the group consisting of donepezil, galantamine, memantine, rivastigmine, and tacrine. 
Pripravak u skladu s patentnim zahtjevom 9, naznačen time što drugo farmaceutsko sredstvo se bira iz skupine koju čine donepezil, galantamin, memantine, rivastigmin, te takrin.
Refrigerated display cabinet with a closing mechanism (1) according to claim 2, where the means for frontal displacement of the movable closing section (3) are supported by the body (4) of the display cabinet (2). 
Rashladna vitrina s mehanizmom za zatvaranje (1) u skladu s patentnim zahtjevom 2, naznačena time što tijelo (4) vitrine (2) nosi element za čeono pomicanje pomičnog odjeljka za zatvaranje (3).
MMVF according to any of claims 13 to 17 wherein the range of variation of the fibre diameter defined as the 84% quantile minus the 16% quantile is less than 3.8 µm, preferably less than 3.4 µm, most preferably less than 2.4 µm. 
MMVF sukladno bilo kojem od patentnih zahtjeva 10 do 14, naznačen time što je promjer varijacije promjera vlakna definiran kao 84% kvantilnih minus 16% kvantilnih je manje od 3,8µm, poželjno manje od 3,4µm, najpogodnije manje od 2,4µm.
R' and R" are, independently, -A, where -A is a formula (II) macrocycle: where Y are the same or different and are selected from the group consisting of hydrogen, straight or branched C1-C4 alkyl, -(CH2)m-COOH, where m is an integer from 1 to 3; 
R' iR" su, nezavisno, -A, gde je -A makrociklus formule (II): (i) gdje su Y isti ili različiti i izabrani su iz grupe koju čine vodik, linearni ili razgranati C,-Cg alkil, (CH>),-COOH, gdje je m cijeli broj od 1 do 3;
An in vitro method for producing activated cytotoxic T lymphocytes (CTL), the method comprising contacting in vitro CTL with antigen loaded human class II MHC molecules expressed on the surface of a suitable antigen-presenting cell for a period of time sufficient to activate said CTL in an antigen specific manner, wherein said antigen is a peptide according to any one of Claims I or 2. 
In vitro metoda za proizvodnju aktiviranih citotoksičnih T limfocita (CTL), pri čemu se metoda sastoji od in vitro doticaja CTL-a s uklopljenim antigenima MHC molekula razreda II, prikazanim na površini prikladne stanice koja prikazuje antigen u vremenskom razdoblju dovoljnom za aktivaciju spomenutog CTL-a na antigen-specifičan način, gdje je spomenuti antigen peptid iz bilo kojeg od Zahtjeva 1 ili 2.
The logic unit 50 signals the dangerous condition by flashing red LED diode 114. 
Logička jedinica 50 signalizira opasno stanje treperenjem crvene LED diode 114.
assembling an anti-refill fitment (14, 114, 214, 414, 614) into the interior passage of the neck of the container such that a bonding material is disposed between the interior surface of the neck of the container and the fitment; and 
(c) sklapanje nastavka koji onemogućuje ponovno punjenje (14. 114, 214, 414, 614) u unutarnjem prolazu grla spremnika, tako da se vezivni materijal stavlja između unutarnje površine grla spremnika i nastavka: i
The method of claim 1 wherein the steam turbine generator is a utility grade steam turbine generator. 
Postupak sukladno zahtjevu 1, pri čemu parna turbina-generator je parna turbina-generator komunalne klase.
converting Compound 15 to Compound 11. 
[image] kako bi se dobilo Spoj 11.